Rezdiffra (Resmetirom) Dosing in Adults 65 and Older

Does Resmetirom Require a Different Dose in Adults Over 65?

No dose adjustment is required solely because a patient is 65 or older. The FDA-approved prescribing information for Rezdiffra states that age did not meaningfully alter resmetirom pharmacokinetics in population analyses conducted during the MAESTRO-NASH trial program. The approved weight-based strategy applies equally across adult age groups: 80 mg once daily for patients whose body weight is below 100 kg, and 100 mg once daily for those at or above 100 kg.

Older adults bring a different clinical profile than the median trial participant. Prescribers should treat the absence of a mandated dose change as a starting point, not a reason to skip the geriatric-specific workup described in the sections below.

How the FDA Label Addresses Age

The Rezdiffra prescribing information reviewed by the FDA in March 2024 notes that population pharmacokinetic modeling across the MAESTRO-NASH cohort found no clinically meaningful effect of age on resmetirom exposure [1]. This is consistent with how several other hepatic-acting drugs behave: because resmetirom is primarily metabolized in the liver via CYP2C8 and UGT1A3, renal clearance changes that commonly accompany aging have limited impact on drug levels [2].

What the MAESTRO-NASH Trial Enrolled

MAESTRO-NASH (NCT03900429) enrolled 966 adults with biopsy-confirmed NASH and fibrosis stage F1B, F2, or F3 [3]. The trial did include patients over 65, though the mean age across arms was approximately 56 years. Subgroup analyses by age were not the primary focus of the published NEJM report, so geriatric-specific efficacy data from this trial are limited. Clinicians should factor that context into shared decision-making conversations with older patients.

Resmetirom Pharmacokinetics Relevant to Older Adults

Hepatic Metabolism and Exposure

Resmetirom is a liver-directed thyroid hormone receptor beta (THR-beta) agonist. Its selectivity for hepatic tissue over cardiac or skeletal muscle tissue is intentional: oral bioavailability is moderate, and first-pass hepatic uptake concentrates the drug at the target organ [4]. Older adults with compensated cirrhosis or early fibrosis are the intended MASH population, so hepatic extraction remains functional enough for normal dosing in most candidates.

Child-Pugh B or C hepatic impairment is a different matter. The prescribing information advises against use in patients with decompensated cirrhosis. Because MASH can progress silently, a fresh Child-Pugh or MELD score at the time of prescribing is warranted for any older patient whose fibrosis stage has not been recently reassessed [5].

Renal Function and Drug Levels

Resmetirom is not renally cleared to a clinically significant extent. The FDA label does not call for dose reduction based on eGFR [1]. Still, older adults often carry comorbidities, such as type 2 diabetes or hypertension, that accelerate renal decline. Knowing the baseline eGFR matters less for resmetirom itself and more for the co-medications that compete with resmetirom at shared transporters, particularly OATP1B1 and OATP1B3 [2].

Body Weight and the 80 mg / 100 mg Threshold

The 100 kg cutoff for dose selection is not an obesity proxy. It is a pharmacokinetically derived threshold. Older adults often have lower lean body mass at the same total weight as younger patients, but the label does not adjust for lean mass or BMI. Prescribers should use actual body weight at the time of initiation and re-evaluate if a patient's weight crosses the 100 kg boundary during therapy [1].

Drug-Drug Interactions in the Geriatric Context

This is the section where age matters most. Adults over 65 take an average of 4.5 prescription medications concurrently, and roughly 36% of community-dwelling adults in this age group take five or more drugs simultaneously [6]. Resmetirom carries interaction warnings that directly overlap with the drug classes most commonly prescribed for older adults with metabolic disease.

Statins: The Highest-Priority Interaction

Resmetirom inhibits OATP1B1 and OATP1B3 hepatic uptake transporters. These transporters govern the hepatic entry of most statins. Co-administration increases statin plasma exposure, raising the risk of statin-associated myopathy [7].

The prescribing information recommends specific statin dose caps when used with resmetirom [1]:

• Simvastatin: no more than 20 mg/day
• Lovastatin: no more than 20 mg/day
• Pitavastatin: no more than 2 mg/day
• Rosuvastatin: no more than 20 mg/day

Older adults with MASH frequently carry a concurrent cardiovascular risk indication for high-intensity statin therapy. Switching from simvastatin 40 mg to rosuvastatin 20 mg, or from rosuvastatin 40 mg to atorvastatin 40 mg (which has a less pronounced OATP1B interaction with resmetirom), may preserve cardiovascular benefit while reducing myopathy risk [8].

CYP2C8 Inhibitors and Inducers

Resmetirom is a CYP2C8 substrate. Strong CYP2C8 inhibitors, such as gemfibrozil, can substantially raise resmetirom exposure. Strong inducers, such as rifampin, can reduce it. Gemfibrozil is sometimes prescribed alongside a statin in older patients with mixed dyslipidemia, making this a double interaction risk: gemfibrozil raises resmetirom levels while also raising statin levels via OATP1B inhibition [9].

Immunosuppressants and Transplant Recipients

Cyclosporine is a potent OATP1B inhibitor and is commonly used in older transplant recipients. The resmetirom label recommends avoiding the combination, or if unavoidable, reducing resmetirom to 80 mg regardless of body weight [1]. Tacrolimus has a less pronounced transporter effect but warrants monitoring.

Geriatric Safety Signals: Falls, Thyroid, and Bone

Falls and Frailty

Resmetirom carries a low intrinsic risk for sedation, orthostatic hypotension, or the other common fall precipitants. In MAESTRO-NASH, the drug was generally well tolerated, with nausea (17.4% at 100 mg vs. 6.4% placebo) and diarrhea (17.2% vs. 6.4%) as the leading adverse events during the first 4 weeks of treatment [3]. Both effects are dose-initiation phenomena that often resolve by week 8. For older adults who are frail or who have low baseline body weight, nausea-related anorexia during the first month is worth monitoring, given the risk of unintended weight loss affecting muscle mass.

Thyroid Function

THR-beta selectivity means resmetirom has minimal off-target thyroid hormone receptor alpha activity, which reduces cardiac and bone risks compared with non-selective thyroid hormone analogs [4]. TSH suppression was not a clinically meaningful finding in MAESTRO-NASH. Still, older adults with pre-existing atrial fibrillation or osteoporosis represent a population where even minor thyromimetic cardiac or bone effects could be clinically significant. A baseline ECG and TSH are reasonable precautions, though not mandated by the label.

Bone Density Considerations

Thyroid receptor alpha stimulation reduces bone mineral density. Because resmetirom's selectivity is for beta receptors, bone density effects are expected to be minimal [10]. The MAESTRO-NASH 52-week data did not identify a bone density safety signal [3]. For older women post-menopause who already carry osteoporosis risk, existing DEXA scan schedules per the U.S. Preventive Services Task Force recommendation for women 65 and older should continue independently of resmetirom initiation [11].

Monitoring Protocol for Older Adults on Resmetirom

Baseline Assessment Before the First Prescription

Before initiating resmetirom in any patient over 65, a focused assessment should cover the following:

1. Liver fibrosis stage confirmation (FibroScan, MRE, or liver biopsy within 12 months)
2. Child-Pugh and MELD scores to confirm compensated disease
3. Full medication reconciliation targeting statin doses, fibrates, cyclosporine, and CYP2C8 inhibitors
4. Baseline ALT, AST, total bilirubin, alkaline phosphatase, and lipid panel
5. Serum creatinine and eGFR for co-medication adjustment purposes
6. TSH if cardiac history or atrial fibrillation is present
7. Body weight for dose tier selection

On-Treatment Monitoring Schedule

The Rezdiffra prescribing information specifies liver chemistry monitoring. For the geriatric population, an extended schedule addresses additional age-specific concerns [1]:

• Week 4: LFTs, weight, GI tolerance check (nausea/diarrhea assessment)
• Month 3: LFTs, fasting lipid panel, statin myopathy symptom screen
• Every 6 months thereafter: LFTs, lipid panel, weight, full medication reconciliation

LDL-cholesterol commonly rises during the first 3 months of resmetirom therapy, a transient effect that reflects redistribution of hepatic cholesterol processing [3]. This is not an indication to stop the drug, but it does argue for baseline lipid documentation and follow-up in older adults already at the margin of their statin dose ceiling.

Comparing 80 mg and 100 mg: Efficacy and Tolerability in Context

MAESTRO-NASH Histological Outcomes

MAESTRO-NASH was a Phase 3, randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2024 [3]. At 52 weeks, the co-primary endpoints were NASH resolution without worsening of fibrosis, and fibrosis improvement by at least one stage without worsening of NASH activity.

• NASH resolution: 25.9% (80 mg) and 29.9% (100 mg) vs. 9.7% placebo (P<0.001 for both doses)
• Fibrosis improvement: 24.2% (80 mg) and 25.9% (100 mg) vs. 14.2% placebo (P<0.001 for both doses)

The 100 mg dose showed a numerically higher NASH resolution rate without a proportionally larger increase in adverse events at 52 weeks, which is why the weight-based dose selection protocol was preserved rather than defaulting all patients to 80 mg [3].

Gastrointestinal Adverse Events by Dose

Nausea was more common at 100 mg (17.4%) than at 80 mg (12.9%), with placebo at 6.4% [3]. For an older adult near the 100 kg boundary, body weight fluctuations from month to month might make the 80 mg vs. 100 mg decision dynamic. Prescribers should re-weigh patients at the 3-month visit and adjust the dose tier if weight has changed materially.

Deprescribing Resmetirom: When to Consider Stopping

MASH is a long-term disease. Resmetirom is not expected to be a short-course therapy in most patients. Discontinuation considerations in older adults include:

• Lack of biochemical response (ALT not declining by at least 17 IU/L from baseline at 12 weeks, based on the MAESTRO secondary marker analysis) [3]
• New onset of decompensated liver disease (Child-Pugh B or C)
• Development of a contraindicated drug interaction that cannot be managed through dose capping or substitution
• Pregnancy in women who retain reproductive capacity (though post-menopausal status applies to most women in the 65+ group)
• Patient-driven deprescribing based on frailty progression or goals-of-care revision

The Beers Criteria, maintained by the American Geriatrics Society and updated in 2023, does not currently list resmetirom as a potentially inappropriate medication for older adults, given the drug's approval date and early post-market experience [12]. However, clinicians should revisit this as pharmacovigilance data accumulate.

Practical Prescribing Steps for the 65+ Patient

Starting resmetirom in an older adult does not require a different prescription form, but it does benefit from a structured sequence:

1. Confirm fibrosis stage F2 or F3 on recent histology or validated non-invasive testing.
2. Weigh the patient and select 80 mg (body weight <100 kg) or 100 mg (body weight ≥100 kg).
3. Reconcile all statin prescriptions and apply the dose caps listed in the FDA label.
4. Discontinue or substitute gemfibrozil if present.
5. Counsel the patient that nausea and diarrhea are common during the first 4 weeks and typically self-resolve.
6. Schedule the 4-week, 3-month, and 6-month monitoring visits before the patient leaves the office.
7. Document the baseline LFT and lipid values to enable meaningful trend comparison at follow-up.

The American Association for the Study of Liver Diseases (AASLD) 2023 guidance on MASH management recommends pharmacotherapy initiation for patients with at-risk NASH (NAS ≥4 with fibrosis ≥F2) when lifestyle intervention alone is insufficient [13]. Resmetirom meets this threshold and is the only FDA-approved agent for this indication as of mid-2025.

As the AASLD Practice Guidance states: "Patients with NASH and significant fibrosis represent a population at elevated risk for liver-related morbidity and mortality and should be considered for pharmacological intervention when available and appropriate." [13]

Special Populations Within the 65+ Age Group

Adults 75 and Older

MAESTRO-NASH did not publish a specific subgroup analysis for adults over 75. Population pharmacokinetic data pooled across the resmetirom clinical program suggest exposure is stable into the seventh and eighth decades of life, but the sample size for patients over 75 in Phase 3 data is not large enough to draw firm conclusions [1]. Prescribers treating octogenarians with MASH should weigh the potential hepatic benefit against overall life expectancy and competing comorbidities.

Older Adults with Type 2 Diabetes

Approximately 50% of MAESTRO-NASH participants had type 2 diabetes at baseline [3]. This is directly relevant to the geriatric population, where MASH and T2D frequently co-occur. Resmetirom does not alter blood glucose directly. GLP-1 receptor agonists such as semaglutide and tirzepatide have shown hepatic benefit in separate trials and may be used concurrently with resmetirom, though head-to-head comparison data are not yet available [14]. The combination has no known pharmacokinetic interaction, though clinical practice guidelines have not yet issued formal co-prescribing recommendations.

Post-Menopausal Women

Post-menopausal women represent a large share of the 65+ MASH population. The pregnancy contraindication is generally not relevant, but clinicians should verify menopausal status in any woman whose reproductive history is unclear. Resmetirom's THR-beta selectivity means minimal interaction with estrogen receptor pathways, so the drug does not require adjustment around concurrent hormone therapy use [10].